Anxiety in Seniors

The safest anxiety medications for seniors are SSRIs (sertraline/Zoloft, escitalopram/Lexapro), SNRIs (duloxetine/Cymbalta), and buspirone (BuSpar). SSRIs are first-line for most anxiety disorders — sertraline is the most-studied for late-life anxiety and panic disorder, while escitalopram is FDA-approved for GAD with the fewest drug interactions. Start doses should be half the adult dose (sertraline 12.5–25mg, escitalopram 5mg) and titrated slowly. Full anxiolytic effect requires 2–6 weeks. Buspirone is significantly underused in seniors despite being the ideal choice for chronic GAD — it has no dependence potential, causes no sedation, no cognitive impairment, and no fall risk. It requires consistent twice-daily dosing and takes 2–4 weeks to work, but is an excellent long-term maintenance option. Benzodiazepines (Xanax, Ativan, Valium, Klonopin) are on the 2023 Beers Criteria explicit AVOID list for seniors due to falls, hip fractures, cognitive impairment, physical dependence, and withdrawal risk. Hydroxyzine (Vistaril) is also on the Beers Criteria avoid list due to anticholinergic effects. Diphenhydramine (Benadryl) — widely self-administered for anxiety and sleep — is highly anticholinergic and should be avoided entirely in seniors.

Benzodiazepines (alprazolam/Xanax, lorazepam/Ativan, diazepam/Valium, clonazepam/Klonopin) are explicitly on the 2023 American Geriatrics Society Beers Criteria AVOID list for seniors, with strong evidence supporting the recommendation. The risks are multiple and serious. Fall and fracture risk: benzodiazepines increase fall risk 2–3 times and hip fracture risk significantly — a hip fracture in a senior over 75 carries 25–35% one-year mortality. Cognitive impairment and delirium: benzodiazepines cause acute confusion, anterograde amnesia, and delirium in seniors — they are one of the most common drug causes of delirium in hospitalized older adults. Physical dependence: tolerance develops within 2–4 weeks, and physical dependence develops with regular use. Withdrawal is severe and can cause seizures — one of only two drug withdrawals (with alcohol) that can be fatal. Paradoxical effects: in approximately 5–10% of seniors, benzos cause paradoxical disinhibition — increased agitation, aggression, and agitation rather than sedation. Long-term cognitive risk: observational studies have linked long-term benzodiazepine use with increased risk of Alzheimer's disease, though causality is debated. Importantly, seniors who have been on benzodiazepines for years should NOT stop abruptly — a physician-supervised slow taper over months is required to safely discontinue.

Yes — anxiety in seniors presents differently in several important ways that contribute to its being underdiagnosed. Somatic presentation: seniors are more likely to present with physical symptoms (muscle tension, fatigue, headaches, gastrointestinal symptoms) than the classic mental symptoms of worry. They often attribute these to 'normal aging' or a physical disease. Providers may also miss the anxiety, ordering extensive physical workups for the somatic symptoms while the underlying anxiety goes untreated. Rationalized worry: unlike younger adults, seniors may have objectively realistic concerns (health decline, financial insecurity, bereavement, loss of independence). This can lead both patients and providers to dismiss anxiety as 'understandable worry about real problems' — but when the worry is disproportionate, persistent, and impairing, it meets the threshold for a treatable disorder regardless of whether the triggers are 'real.' Comorbid medical illness: anxiety is far more likely to coexist with chronic medical conditions in seniors (COPD, heart disease, chronic pain, cancer) than in younger adults. Medical illness can both cause and worsen anxiety. Dementia overlap: anxiety is extremely common in the early stages of dementia — in some patients, anxiety and agitation are earlier symptoms than memory loss. Assessment for both conditions is warranted. Late-onset PTSD: retirement, health events, and loss of routine can unmask PTSD symptoms that were previously suppressed by work and social structure in combat veterans or abuse survivors.

Anxiety in seniors is diagnosed through clinical interview and validated screening tools, after ruling out medical causes. The GAD-7 (Generalized Anxiety Disorder 7-item scale) is the most widely used screening tool — a score of 5–9 suggests mild anxiety, 10–14 moderate, and ≥15 severe. The GAD-2 (two questions from the GAD-7) is a quick primary care screen. The PHQ-4 combines the GAD-2 and PHQ-2 to simultaneously screen for both anxiety and depression, which frequently co-occur. Before attributing symptoms to anxiety, medical causes must be excluded: TSH (hyperthyroidism mimics anxiety), HbA1c and fasting glucose (hypoglycemia in diabetics), ECG or Holter monitor (arrhythmia), medication review (decongestants, albuterol, caffeine, levothyroxine over-replacement), CBC and B12 (deficiency). A full psychiatric history should explore prior anxiety episodes, trauma history (for PTSD), family history, substance use (alcohol dependence causes anxiety and withdrawal), and current medications including OTC drugs and supplements (many senior-common supplements can worsen anxiety — ginseng, guarana, high-dose vitamin D, ephedra-containing products).

Yes — anxiety has significant bidirectional relationships with physical health in seniors, and untreated anxiety worsens outcomes across multiple medical conditions. Cardiovascular disease: chronic anxiety activates the sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol, increasing heart rate, and promoting inflammation. Anxiety is an independent risk factor for cardiac events and worsens outcomes after myocardial infarction. Anxiety also triggers and worsens atrial fibrillation. COPD: anxiety and COPD create a vicious cycle — dyspnea triggers anxiety, which worsens breathlessness through hyperventilation, which worsens COPD symptoms. COPD patients with comorbid anxiety have more hospitalizations and worse mortality. Fall risk: anxiety causes hypervigilance and muscle tension but paradoxically impairs the relaxed, confident gait needed for safe walking. Anxious seniors also avoid physical activity out of fear of falling, which leads to deconditioning that actually increases fall risk. Sleep: anxiety-driven rumination and hyperarousal are the most common causes of chronic insomnia in seniors. Poor sleep then amplifies anxiety — a bidirectional cycle. Cognitive decline: chronic stress and anxiety elevate cortisol, which damages the hippocampus (the memory center) over time. Anxiety is increasingly recognized as a risk factor for dementia, not just a symptom of it.

Multiple non-medication treatments have strong evidence for anxiety in seniors — some as effective as medication and without side effects. Cognitive Behavioral Therapy (CBT) has Level I evidence (multiple RCTs) and is recommended as first-line by most clinical guidelines, either alone or combined with medication. CBT for late-life anxiety addresses the cognitive distortions (catastrophizing, overestimating threat) and avoidance behaviors that maintain anxiety. It is available in-person, via telehealth (increasingly accessible for homebound seniors), and through structured digital programs. Relaxation training — progressive muscle relaxation and diaphragmatic breathing — directly counteracts the physical symptoms of anxiety (muscle tension, hyperventilation) by activating the parasympathetic nervous system. Exercise has anxiolytic effects equivalent to medication for mild-to-moderate anxiety per several meta-analyses — aerobic exercise 30 minutes 5 days per week produces measurable cortisol reduction. Tai chi has specific Level II evidence for anxiety in seniors with chronic pain and balance problems. Mindfulness-Based Stress Reduction (MBSR) — the 8-week structured program — significantly reduces anxiety and has the added benefit of reducing pain catastrophizing and improving sleep. Social engagement addresses a major driver of anxiety in seniors: isolation. Structured social activities through senior centers, faith communities, and volunteer programs reduce anxiety while providing meaning and routine. The Collaborative Care model — coordinating mental health care with primary care — produces significantly better outcomes than usual care for late-life anxiety.

Anxiety is one of the most common behavioral and psychological symptoms of dementia (BPSD) — occurring in 40–70% of dementia patients at some point. It presents as persistent restlessness, repetitive questioning, shadowing caregivers, or agitation around routine changes. The challenge is that standard anxiety assessments (GAD-7, self-report) are unreliable in moderate-to-advanced dementia — observational tools designed for dementia, such as the Rating Anxiety in Dementia (RAID) scale or the Neuropsychiatric Inventory (NPI), are more useful. Non-pharmacological approaches are strongly preferred as first-line: structured daily routine reduces uncertainty that drives anxiety, therapeutic activities (music, reminiscence, sensory stimulation), caregiver training, and environmental modifications (clear signage, familiar objects, reduced overstimulation). When medication is needed: SSRIs (sertraline, escitalopram) have the best evidence for anxiety in dementia and the best safety profile. Buspirone may help but evidence is weaker in cognitively impaired patients. Atypical antipsychotics (quetiapine, risperidone) are sometimes used for severe agitation — they carry an FDA black box warning for increased mortality in elderly patients with dementia and should be reserved for cases where the risk-benefit clearly favors their use. Benzodiazepines should be avoided in dementia — they cause disproportionate cognitive worsening and delirium.